Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 8/20 | 0.36 |
| ▸ | HTR1A | P08908 | 7/20 | 0.36 |
| ▸ | DRD2 | P14416 | 7/20 | 0.36 |
| ▸ | HTR7 | P34969 | 7/20 | 0.36 |
| ▸ | HTR6 | P50406 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812182 | 0.88 | HTR1A (0.48) | EIF2AK2HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2814442 | 0.87 | CLPP (0.39) | MAPT | |
| SCHEMBL2816737 | 0.82 | ACHE (0.37) | MAPT | |
| SCHEMBL2816693 | 0.82 | CCNE2 (0.40) | EIF2AK2HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2814358 | 0.81 | IP6K1 (0.44) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL2811032 | 0.81 | CLPP (0.40) | HTR6NPSR1POLB | |
| SCHEMBL2814261 | 0.81 | CLPP (0.39) | RAB9A | |
| SCHEMBL14405859 | 0.81 | HRH4 (0.41) | HTR2AHTR7HTR6HRH3POLB | |
| SCHEMBL2808392 | 0.81 | CCNE2 (0.49) | EIF2AK2HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL2816451 | 0.80 | CLPP (0.39) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | EIF2AK2 1147/4885HTR2A 2863/4885HTR1A 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.